Clinical Trial Update: A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke. [Phase 2]

View source ↗

Summary

Phase II trial update for an injection of recombinant human tissue plasminogen kinase derivative in acute ischemic stroke.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke

Drugs mentioned

• recombinant human tissue plasminogen kinase derivative

Snippet

Sponsor: Angde Biotech Pharmaceutical Co., Ltd. | Conditions: Acute Ischemic Stroke | Phase 2 | Status: UNKNOWN